Morningside Venture Investments Ltd
CIK 0001543112 Name as filed on the most recent filing
Filed as Morningside Venture Investments Ltd (32)
55 transaction lines · from 32 filings · filed 2017-11-13 to 2026-08-05 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.
A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.
Issuers this insider has filed against
Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-20 05:22 UTC.
- ISSUER Apnimed, Inc. 1 filings
- ISSUER Amylyx Pharmaceuticals, Inc. 10 filings
- ISSUER Kezar Life Sciences, Inc. 12 filings
- ISSUER GreenLight Biosciences Holdings, PBC 3 filings
- ISSUER Apellis Pharmaceuticals, Inc. 6 filings
No issuer is recorded
The catalog holds no filing linking this CIK to an issuer.
Transactions
Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.
53 transactions · Newest transaction date first, id breaking the tie.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-20 05:22 UTC.
| Direction | Date | Issuer | Code | Shares | Price | Value USD | Filing |
|---|---|---|---|---|---|---|---|
| 2026-08-03 |
Apnimed, Inc. APMD |
P, Open-market purchase | 312,500 acquired | 16.00 | 5,000,000.00 | Form 4, filing 0000905148-26-003483 | |
| 2023-03-29 |
Amylyx Pharmaceuticals, Inc. AMLX |
S, Open-market sale | 29,048 disposed | 30.45 | 884,511.60 | Form 4, filing 0000899243-23-010078 | |
| 2023-03-28 |
Amylyx Pharmaceuticals, Inc. AMLX |
S, Open-market sale | 100,000 disposed | 30.37 | 3,037,000.00 | Form 4, filing 0000899243-23-009972 | |
| 2023-03-27 |
Amylyx Pharmaceuticals, Inc. AMLX |
S, Open-market sale | 32,964 disposed | 30.25 | 997,161.00 | Form 4, filing 0000899243-23-009972 | |
| 2023-03-27 |
Amylyx Pharmaceuticals, Inc. AMLX |
S, Open-market sale | 28,000 disposed | 30.80 | 862,400.00 | Form 4, filing 0000899243-23-009972 | |
| 2023-03-21 |
Amylyx Pharmaceuticals, Inc. AMLX |
S, Open-market sale | 34,641 disposed | 31.69 | 1,097,773.29 | Form 4, filing 0000899243-23-009506 | |
| 2023-03-21 |
Amylyx Pharmaceuticals, Inc. AMLX |
S, Open-market sale | 28,807 disposed | 32.17 | 926,721.19 | Form 4, filing 0000899243-23-009506 | |
| 2023-03-16 |
Amylyx Pharmaceuticals, Inc. AMLX |
S, Open-market sale | 9,122 disposed | 32.55 | 296,921.10 | Form 4, filing 0000899243-23-008858 | |
| 2023-03-15 |
Amylyx Pharmaceuticals, Inc. AMLX |
S, Open-market sale | 108,934 disposed | 33.12 | 3,607,894.08 | Form 4, filing 0000899243-23-008733 | |
| 2023-03-15 |
Amylyx Pharmaceuticals, Inc. AMLX |
S, Open-market sale | 41,066 disposed | 33.68 | 1,383,102.88 | Form 4, filing 0000899243-23-008733 | |
| 2023-03-14 |
Amylyx Pharmaceuticals, Inc. AMLX |
S, Open-market sale | 70,714 disposed | 34.54 | 2,442,461.56 | Form 4, filing 0000899243-23-008733 | |
| 2023-03-02 |
Amylyx Pharmaceuticals, Inc. AMLX |
S, Open-market sale | 50,000 disposed | 33.75 | 1,687,500.00 | Form 4, filing 0000899243-23-007120 | |
| 2023-02-23 |
Amylyx Pharmaceuticals, Inc. AMLX |
S, Open-market sale | 48,889 disposed | 35.55 | 1,738,003.95 | Form 4, filing 0000899243-23-006123 | |
| 2023-02-23 |
Amylyx Pharmaceuticals, Inc. AMLX |
S, Open-market sale | 1,111 disposed | 36.24 | 40,262.64 | Form 4, filing 0000899243-23-006123 | |
| 2023-02-22 |
Amylyx Pharmaceuticals, Inc. AMLX |
S, Open-market sale | 39,916 disposed | 35.91 | 1,433,383.56 | Form 4, filing 0000899243-23-006123 | |
| 2023-02-22 |
Amylyx Pharmaceuticals, Inc. AMLX |
S, Open-market sale | 10,084 disposed | 36.34 | 366,452.56 | Form 4, filing 0000899243-23-006123 | |
| 2023-02-22 |
Amylyx Pharmaceuticals, Inc. AMLX |
S, Open-market sale | 47,888 disposed | 34.70 | 1,661,713.60 | Form 4, filing 0000899243-23-006394 | |
| 2023-02-22 |
Amylyx Pharmaceuticals, Inc. AMLX |
S, Open-market sale | 2,112 disposed | 35.34 | 74,638.08 | Form 4, filing 0000899243-23-006394 | |
| 2023-02-06 |
Kezar Life Sciences, Inc. KZR |
S, Open-market sale | 40,000 disposed | 6.88 | 275,320.00 | Form 4, filing 0000899243-23-004187 | |
| 2023-02-03 |
Kezar Life Sciences, Inc. KZR |
S, Open-market sale | 25,000 disposed | 7.15 | 178,650.00 | Form 4, filing 0000899243-23-004187 | |
| 2023-02-02 |
Kezar Life Sciences, Inc. KZR |
S, Open-market sale | 50,000 disposed | 7.19 | 359,500.00 | Form 4, filing 0000899243-23-003869 | |
| 2023-02-01 |
Kezar Life Sciences, Inc. KZR |
S, Open-market sale | 40,000 disposed | 6.95 | 278,000.00 | Form 4, filing 0000899243-23-003869 | |
| 2023-01-31 |
Kezar Life Sciences, Inc. KZR |
S, Open-market sale | 30,000 disposed | 7.08 | 212,400.00 | Form 4, filing 0000899243-23-003120 | |
| 2023-01-30 |
Kezar Life Sciences, Inc. KZR |
S, Open-market sale | 30,000 disposed | 6.91 | 207,300.00 | Form 4, filing 0000899243-23-003120 | |
| 2023-01-25 |
Kezar Life Sciences, Inc. KZR |
S, Open-market sale | 50,000 disposed | 6.85 | 342,500.00 | Form 4, filing 0000899243-23-002854 | |
| 2023-01-24 |
Kezar Life Sciences, Inc. KZR |
S, Open-market sale | 80,000 disposed | 6.98 | 558,400.00 | Form 4, filing 0000899243-23-002677 | |
| 2023-01-23 |
Kezar Life Sciences, Inc. KZR |
S, Open-market sale | 80,000 disposed | 6.81 | 544,800.00 | Form 4, filing 0000899243-23-002677 | |
| 2023-01-17 |
Kezar Life Sciences, Inc. KZR |
S, Open-market sale | 6,114 disposed | 6.79 | 41,514.06 | Form 4, filing 0000899243-23-002157 | |
| 2023-01-13 |
Kezar Life Sciences, Inc. KZR |
S, Open-market sale | 1,971 disposed | 7.15 | 14,092.65 | Form 4, filing 0000899243-23-001846 | |
| 2023-01-12 |
Kezar Life Sciences, Inc. KZR |
S, Open-market sale | 5,000 disposed | 6.77 | 33,850.00 | Form 4, filing 0000899243-23-001846 | |
| 2023-01-06 |
Kezar Life Sciences, Inc. KZR |
S, Open-market sale | 3,000 disposed | 6.89 | 20,670.00 | Form 4, filing 0000899243-23-001293 | |
| 2023-01-05 |
Kezar Life Sciences, Inc. KZR |
S, Open-market sale | 12,162 disposed | 6.97 | 84,769.14 | Form 4, filing 0000899243-23-001293 | |
| 2023-01-04 |
Kezar Life Sciences, Inc. KZR |
S, Open-market sale | 30,000 disposed | 7.17 | 215,100.00 | Form 4, filing 0000899243-23-000979 | |
| 2023-01-03 |
Kezar Life Sciences, Inc. KZR |
S, Open-market sale | 500 disposed | 7.10 | 3,550.00 | Form 4, filing 0000899243-23-000979 | |
| 2022-12-29 |
Kezar Life Sciences, Inc. KZR |
S, Open-market sale | 25,000 disposed | 7.10 | 177,500.00 | Form 4, filing 0000899243-23-000979 | |
| 2022-10-04 |
Kezar Life Sciences, Inc. KZR |
S, Open-market sale | 3,612 disposed | 8.82 | 31,857.48 | Form 4, filing 0000899243-22-032974 | |
| 2022-10-03 |
Kezar Life Sciences, Inc. KZR |
S, Open-market sale | 28,700 disposed | 8.78 | 251,957.30 | Form 4, filing 0000899243-22-032974 | |
| 2022-08-11 |
GreenLight Biosciences Holdings, PBC GRNA |
P, Open-market purchase | 3,061,224 acquired | 3.92 | 11,999,998.08 | Form 4, filing 0000899243-22-028680 | |
| 2022-02-02 |
GreenLight Biosciences Holdings, PBC GRNA |
P, Open-market purchase | 1,000,000 acquired | Not reported | Not priced | Form 4, filing 0000899243-22-011429 | |
| 2022-02-02 |
GreenLight Biosciences Holdings, PBC ENVI |
P, Open-market purchase | 1,000,000 acquired | Not reported | Not priced | Form 4, filing 0000899243-22-004855 | |
| 2022-01-11 |
Amylyx Pharmaceuticals, Inc. AMLX |
P, Open-market purchase | 263,158 acquired | 19.00 | 5,000,002.00 | Form 4, filing 0000899243-22-011432 | |
| 2022-01-11 |
Amylyx Pharmaceuticals, Inc. AMLX |
P, Open-market purchase | 263,158 acquired | 19.00 | 5,000,002.00 | Form 4, filing 0000899243-22-003157 | |
| 2021-11-18 |
Apellis Pharmaceuticals, Inc. APLS |
P, Open-market purchase | 250,000 acquired | 40.00 | 10,000,000.00 | Form 4, filing 0000899243-21-045265 | |
| 2020-02-04 |
Kezar Life Sciences, Inc. KZR |
P, Open-market purchase | 3,800,000 acquired | 2.60 | 9,880,000.00 | Form 4, filing 0001104659-20-011907 | |
| 2020-01-13 |
Apellis Pharmaceuticals, Inc. APLS |
P, Open-market purchase | 540,540 acquired | 37.00 | 19,999,980.00 | Form 4, filing 0000899243-20-001530 | |
| 2019-03-11 |
Apellis Pharmaceuticals, Inc. APLS |
P, Open-market purchase | 441,176 acquired | 17.00 | 7,499,992.00 | Form 4, filing 0001104659-19-014545 | |
| 2018-09-21 |
Apellis Pharmaceuticals, Inc. APLS |
P, Open-market purchase | 40,000 acquired | 19.84 | 793,600.00 | Form 4, filing 0000899243-18-025079 | |
| 2018-09-20 |
Apellis Pharmaceuticals, Inc. APLS |
P, Open-market purchase | 21,724 acquired | 19.43 | 422,097.32 | Form 4, filing 0000899243-18-025079 | |
| 2018-09-20 |
Apellis Pharmaceuticals, Inc. APLS |
P, Open-market purchase | 19,599 acquired | 18.79 | 368,265.21 | Form 4, filing 0000899243-18-025079 | |
| 2018-09-19 |
Apellis Pharmaceuticals, Inc. APLS |
P, Open-market purchase | 60,000 acquired | 18.09 | 1,085,400.00 | Form 4, filing 0000899243-18-024796 |
This column is intentionally blank
No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.
- P, Open-market purchase
- Open-market purchase
- S, Open-market sale
- Open-market sale
Every value is as reported on the Form 4. A price the filing did not report is marked Not reported and no value is computed from it. Codes outside the open market, drawn in grey behind a dashed rule, are compensation and administrative machinery rather than a decision to trade at the prevailing price.
What this insider's stored lines contain
Exact counts over every stored line for this entity. This is a statement of composition, not a filter: the only filter this page offers is the open-market one above, because that is the only one an index serves today.
- Open-market purchase 17
- Open-market sale 36
- Option exercise 0
- Grant or award 0
- Tax withholding 0
- Disposition to the issuer 0
- In-the-money option exercise 0
How to cite this page
ebomi catalog. Morningside Venture Investments Ltd, insider transactions. Retrieved 2026-08-20 from https://ebomi.com/insider/0001543112
Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6